This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klemens, S. P.
Right arrow Articles by Cynamon, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klemens, S. P.
Right arrow Articles by Cynamon, M. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 02 1996, 298-301, Vol 40, No. 2
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model

SP Klemens and MH Cynamon
Department of Medicine, SUNY Health Science Center, Syracuse 13210, USA.

The activity of KRM-1648, alone and in combination with isoniazid, was compared with those of isoniazid, rifampin, and the combination of rifampin plus isoniazid in a murine model of tuberculosis. Four-week- old female CD-1 mice were infected intravenously with approximately 10(7) viable Mycobacterium tuberculosis ATCC 35801 organisms. Treatment was started 1 week postinfection and was given by gavage 5 days per week. The duration of the treatment phase was 12 weeks, with groups of mice sacrificed at 2, 4, 6, 8, and 12 weeks. For the observation phase, additional groups of treated mice were sacrificed at 4, 8, 16, and 24 weeks after the cessation of treatment. Viable cell counts were determined from homogenates of the spleens and the right lungs. KRM- 1648 was the most active single agent evaluated and resulted in no detectable CFUs in the spleens and lungs by the end of 6 weeks of treatment. Neither rifampin nor isoniazid reduced cell counts to undetectable levels, even after 12 weeks of treatment. The combination of KRM-1648 plus isoniazid was much more active than rifampin plus isoniazid. KRM-1648 plus isoniazid resulted in the apparent sterilization of organs at 6 months following the cessation of treatment. The promising activity of KRM-1648 may allow for ultrashort- course therapy of tuberculosis, i.e., treatment regimens of 4 months or less.


This article has been cited by other articles:

  • Anton, P. M., O'Brien, M., Kokkotou, E., Eisenstein, B., Michaelis, A., Rothstein, D., Paraschos, S., Kelly, C. P., Pothoulakis, C. (2004). Rifalazil Treats and Prevents Relapse of Clostridium difficile-Associated Diarrhea in Hamsters. Antimicrob. Agents Chemother. 48: 3975-3979 [Abstract] [Full Text]  
  • Cynamon, M. H., Sklaney, M. (2003). Gatifloxacin and Ethionamide as the Foundation for Therapy of Tuberculosis. Antimicrob. Agents Chemother. 47: 2442-2444 [Abstract] [Full Text]  
  • Iseman, M.D. (2002). Tuberculosis therapy: past, present and future. Eur Respir J 20: 87S-94s [Abstract] [Full Text]  
  • Dietze, R., Teixeira, L., Rocha, L. M. C., Palaci, M., Johnson, J. L., Wells, C., Rose, L., Eisenach, K., Ellner, J. J. (2001). Safety and Bactericidal Activity of Rifalazil in Patients with Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 45: 1972-1976 [Abstract] [Full Text]  
  • Lenaerts, A. M., Chase, S. E., Cynamon, M. H. (2000). Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model. Antimicrob. Agents Chemother. 44: 3167-3168 [Abstract] [Full Text]  
  • Shoen, C. M., Chase, S. E., DeStefano, M. S., Harpster, T. S., Chmielewski, A. J., Cynamon, M. H. (2000). Evaluation of Rifalazil in Long-Term Treatment Regimens for Tuberculosis in Mice. Antimicrob. Agents Chemother. 44: 1458-1462 [Abstract] [Full Text]  
  • Cynamon, M. H., Zhang, Y., Harpster, T., Cheng, S., DeStefano, M. S. (1999). High-Dose Isoniazid Therapy for Isoniazid-Resistant Murine Mycobacterium tuberculosis Infection. Antimicrob. Agents Chemother. 43: 2922-2924 [Abstract] [Full Text]  
  • Lenaerts, A. M. J. A., Chase, S. E., Chmielewski, A. J., Cynamon, M. H. (1999). Evaluation of Rifapentine in Long-Term Treatment Regimens for Tuberculosis in Mice. Antimicrob. Agents Chemother. 43: 2356-2360 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»